Neuro Discovery

NeuroDiscovery was an Australian biopharmaceutical company dedicated to the discovery and development of treatments for neurological conditions, with a specific focus on pain and sleep disorders. The company operated through a unique model that paired an internal drug development pipeline with a commercial contract research organization, NeuroSolutions Ltd, based in the United Kingdom. Its lead clinical assets included NSL-043 for neuropathic pain and NSL-101 for insomnia, both of which were small molecule candidates. NeuroDiscovery was publicly traded on the Australian Securities Exchange under the ticker NDI. In 2014, the company was acquired by Suda Ltd, which integrated NeuroDiscovery's neurology expertise and its revenue-generating CRO services into its own portfolio.